Elusys Therapeutics, Inc.
about us Elusys & Biodefense product news&events careers
Elusys Overview Leadership
Executive Team Board of  Directors
Anthrax & Bioterrorism Contract Experience Useful Links
Anthim Anthrax Antibody Anthim Publication
Press Releases Presentations
Our Values Working at Elusys Open Positions Benefits Location

NEWS & EVENTS

PRESS RELEASES 2011

view archives

 

October 24, 2011

Elusys initiates third clinical safety study of Anthim, a new anthrax treatment; company successfully completes manufacturing at commercial scale

 
September 8, 2011

Elusys awarded $68 million contract to develop Anthim for intramuscular pre- and post-exposure prophylaxis of anthrax infection

 
January 11, 2011

Regulatory Affairs Executive, Greg Torre, PhD, Esq, Joins Elusys Therapeutics Management Team

 

 

 

 

 

 

 

 

  • Copyright© 2012 Elusys Therapeutics, Inc. All Rights Reserved.
  • contact us
  • site map
  • careers